CDK4/6 Inhibitors

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Introduction Metastatic Breast Cancer

Mechanisms of Endocrine Resistance

MONALEESA-2 Ribociclib Plus Letrozole vs Letrozole Plus Placebo

PFS in MONALEESA-2

MONALEESA-2 Updated Results

MONALEESA-2: Grade 3/4 AEs

Ongoing Ribociclib Clinical Trials

Abemaciclib

MONARCH 2: Abemaciclib in Progressive Disease

PALOMA-1: First-Line Therapy With Palbociclib

PALOMA-2: First-Line Therapy With Palbociclib

PALOMA-3: Palbociclib in Progressive Disease

Management of ER+ Metastatic Breast Cancer in 2017

Neutropenia Management and Monitoring

QT Prolongation Management and Monitoring

Liver Toxicity Management and Monitoring

Conclusions

Abbreviations

Abbreviations (cont)